Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion

Modern Pathology

Volumn 22, Issue 7, 2009, Pages 866-871

  Guo, Charles C ^a   Zuo, Geyan ^a   Cao, Dongdong ^a   Troncoso, Patricia ^a   Czerniak, Bogdan A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Multifocal; Peripheral zone; Prostate cancer; TMPRSS2ERG gene fusion; Transition zone

Indexed keywords

MEMBRANE PROTEIN; SERINE PROTEINASE; TRANSMEMBRANE PROTEIN SERINE PROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; ONCOGENE ERG; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

ADENOCARCINOMA; AGED; GENE FUSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 67650668168     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.57     Document Type: Article

References (23)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
2. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396- 3400.
3. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80.
4. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243.
5. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544.
6. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695.
7. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406.
8. McNeal JE. The zonal anatomy of the prostate. Prostate 1981;2:35-49.
9. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-633.
10. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
11. Shannon BA, McNeal JE, Cohen RJ. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behavior. Pathology 2003;35:467-471.
12. Greene DR, Wheeler TM, Egawa S, et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991;146:1069-1076.
13. Noguchi M, Stamey TA, Neal JE, et al. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000;163: 1751-1755.
14. Noel EE, Ragavan N, Walsh MJ, et al. Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland. Prostate Cancer Prostatic Dis 2008;11:173-180.
15. van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH, et al. Gene expression profiling of the human prostate zones. BJU Int 2006;98:886-897.
16. Erbersdobler A, Fritz H, Schnöger S, et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 2002;41:40-46.
17. Sakai I, Harada K, Hara I, et al. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. BJU Int 2005;96:528-532.
18. Chen ME, Johnston DA, Tang K, et al. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000;89:1800-1809.
19. Garcia JJ, Al-Ahmadie HA, Gopalan A, et al. Do prostatic transition zone tumors have a distinct morphology? Am J Surg Pathol 2008;32:1709-1714.
20. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-2366.
21. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-237.
22. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-633.
23. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67: 7991-7995.